Avid Bioservices Inc (NASDAQ: CDMO) reported Q2 FY24 sales of $25.4 million, down 27% Y/Y, primarily attributed to fewer year-to-date manufacturing runs, a reduction in process development services from early-stage customers, and a reduction of revenue for changes in estimated variable consideration un